ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Urinary Bladder Neoplasms
Eli Lilly and Companyantibody_drug_conjugatePhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
23 Active assets in the Urinary Bladder Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Merck Sharp & Dohme LLC | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Merck Sharp & Dohme LLC | Phase 2 | BB |
Pembrolizumab Eli Lilly and Company | Phase 2 | BB |
Nivolumab Ikena Oncology | Phase 2 | B |
Tetrahydrouridine National Cancer Institute (NCI) | Phase 2 | B |
View all 37 →
Same molecule, other indications
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →